Condition: Narcolepsy · Cataplexy · Excessive Daytime Somnolence · Sponsor: Avadel
An Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Sleep Disorders Center of Alabama | Birmingham, Alabama, United States | — |
| Stanford Sleep Medicine | Redwood City, California, United States | — |
| SDS Clinical Trials | Santa Ana, California, United States | — |
| Alpine Clinical Research Center | Boulder, Colorado, United States | — |
| Delta Waves, Inc. | Colorado Springs, Colorado, United States | — |
| Pulmonary Disease Specialists, PA | Kissimmee, Florida, United States | — |
| Sleep Medicine Specialists of South Florida | Miami, Florida, United States | — |
| FL Pediatric Research Institute | Winter Park, Florida, United States | — |
| NeuroTrials Research Inc | Atlanta, Georgia, United States | — |
| SleepCare Research Institute, Inc. d/b/a Clinical Research Institute | Stockbridge, Georgia, United States | — |
| Fort Wayne Neurological | Fort Wayne, Indiana, United States | — |
| Helene A. Emsellem, MD PC | Chevy Chase, Maryland, United States | — |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04451668